Pain Away sale completed, Wellnex Life turns focus to core analgesics business
Wellnex Life (ASX/AIM: WNX) has completed and settled the sale of its Pain Away business and assets to Mentholatum Australasia Pty Ltd. All conditions precedent to the formal binding agreement have been satisfied, following shareholder approval received at the extraordinary general meeting held on 8 September 2026. The upfront purchase price has been settled, closing out a transaction first announced on 6 August 2026.
When big ASX news breaks, our subscribers know first
What Wellnex Life looks like after the deal
With the divestiture now finalised, Wellnex Life retains its established liquid soft gel analgesics business, underpinned by the company’s own Therapeutic Goods Administration (TGA) marketing authorisations. The remaining business also includes a contract manufacturing operation described as capital-light, with growing international reach.
The board has indicated that cash proceeds from the transaction will be directed towards two immediate priorities: retiring existing debt and supporting working capital for continuing operations. Debt retirement removes a balance sheet overhang that had weighed on the company, while the capital-light nature of the remaining business signals lower ongoing capital requirements going forward.
The Pain Away sale to Mentholatum was structured at up to A$21.3 million, with A$19.8 million payable at completion and up to A$1.5 million in earn-out tied to post-completion EBITDA, a breakdown that contextualises just how transformative the divestiture is relative to Pain Away’s FY2025 revenue contribution of A$13.38 million.
The board is also reviewing options to deliver best value for shareholders, framing the post-sale period as a strategic reset rather than a period of uncertainty.
Understanding TGA marketing authorisations and why they matter
The TGA is Australia’s regulator for therapeutic goods, including medicines, medical devices, and complementary health products. Any product sold in Australia as a therapeutic good must be assessed and listed or registered on the Australian Register of Therapeutic Goods, a process overseen by the TGA.
A TGA marketing authorisation is the formal approval that allows a company to supply a therapeutic product in the Australian market. Holding your own authorisations, rather than licensing them from a third party, is a meaningful commercial advantage. It gives the holder independent control over how, when, and where products are commercialised, without relying on another company’s permissions or being subject to licensing terms that could change.
For Wellnex Life, owning its TGA marketing authorisations means the remaining analgesics business operates with genuine commercial independence. As the company pursues growing international reach through its contract manufacturing model, that regulatory foundation in Australia provides a credible platform from which to expand.
What’s next for Wellnex Life
The company’s near-term priorities are straightforward based on what has been disclosed. The stated uses of proceeds from the transaction are:
- Retire existing debt
- Support working capital for continuing operations
Wellnex Life has indicated it will provide a further update to shareholders in due course. The announcement does not disclose the specific options the board is considering, and no further detail on that process has been provided at this stage.
The completed sale marks a clear inflection point for Wellnex Life, leaving behind the Pain Away brand to concentrate resources on a focused, TGA-authorised analgesics and contract manufacturing business with an international dimension.
The Haleon manufacturing agreement, extended to March 2027, anchors the retained business with a confirmed revenue stream from one of the world’s largest consumer healthcare companies, covering the supply of soft gel liquid paracetamol products manufactured by Wellnex’s wholly owned subsidiary BSPS Aust Pty Ltd.
Don’t Miss the Next Consumer Sector Mover
Big News Blast, the FREE alert service from StockWire X, delivers breaking ASX consumer sector news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button to start receiving alerts the moment market-moving announcements drop.